The consequences of inadequate circulating blood volume are life-threatening. Recognition of hemorrhage by classic physiological signs is important for clinicians to diagnose shock and prevent both short-term and long-term complications (Garrioch 2004).

Control of hemorrhage in the earliest phases of care, recognition and monitoring of individual risk factors, and therapeutic modulation of the inflammatory immune response will probably constitute the next generation of therapy in hemorrhagic shock (Angele 2008).

Early recognition and, correspondingly, early intervention before the onset of multiple organ dysfunction have been demonstrated to decrease morbidity and mortality in critically ill patients (Strehlow 2010).

Hemorrhagic shock is the leading cause of death among trauma patients in both civilian and military settings. It is also well documented, time being the critical factor directly affecting patient outcome.

The need for the early detection and accurate evaluation of blood volume to influence improved patient outcomes is apparent. Current and future economic demands to reduce costs, increase quality and participate in healthcare performance incentives will drive additional needs and challenges.

Challenges inspire innovation; at Zynex® Monitoring Solutions we share the same vision and goals in improving the quality of care for patients with the development of a blood volume monitor. Designed to assist physicians and hospital staff in the early detection of blood loss, reducing: patient morbidity, clinical evaluation time, and the cost of patient care.

Being compact, the Zynex BVM is portable and will be able to operate anywhere in the hospital setting to assist with trauma, intraoperative and postoperative patients.